300267 尔康制药
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.060-3.9510.928-14.8413.310
总资产报酬率 ROA (%)0.053-3.4460.814-13.0903.168
投入资产回报率 ROIC (%)0.055-3.6060.856-13.7523.038

边际利润分析
销售毛利率 (%)29.87320.42422.22023.34122.781
营业利润率 (%)0.304-11.5930.737-36.6199.134
息税前利润/营业总收入 (%)-0.163-11.1511.634-37.6068.990
净利润/营业总收入 (%)-0.104-12.4421.982-35.7107.613

收益指标分析
经营活动净收益/利润总额(%)-1,676.64456.875-66.062-4.14951.442
价值变动净收益/利润总额(%)118.9134.561108.424-2.05061.592
营业外收支净额/利润总额(%)-12.143-3.91720.5963.219-7.969

偿债能力分析
流动比率 (X)2.7822.8692.8833.9013.554
速动比率 (X)1.6511.7231.7502.4682.553
资产负债率 (%)12.55912.21113.74010.27812.300
带息债务/全部投入资本 (%)7.0837.0757.7155.016--
股东权益/带息债务 (%)1,294.2051,295.7901,177.6521,870.7341,255.416
股东权益/负债合计 (%)700.469722.818627.794868.961709.672
利息保障倍数 (X)0.375-2,082.7662.314-162.26616.962

营运能力分析
应收账款周转天数 (天)35.56324.51530.81143.5070.000
存货周转天数 (天)324.093191.927190.048154.5020.000